[go: up one dir, main page]

AR028959A1 - Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares - Google Patents

Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares

Info

Publication number
AR028959A1
AR028959A1 ARP010102877A ARP010102877A AR028959A1 AR 028959 A1 AR028959 A1 AR 028959A1 AR P010102877 A ARP010102877 A AR P010102877A AR P010102877 A ARP010102877 A AR P010102877A AR 028959 A1 AR028959 A1 AR 028959A1
Authority
AR
Argentina
Prior art keywords
rapamycin
manufacture
cardiovascular diseases
medicinal product
treat cardiovascular
Prior art date
Application number
ARP010102877A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22789625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR028959(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR028959A1 publication Critical patent/AR028959A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de una cantidad eficaz de una rapamicina para la manufactura de un medicamento para tratar o inhibir enfermedades cardiovasculares, enfermedades vasculares cerebrales o enfermedades vasculares periféricas en un mamífero que lo necesite.
ARP010102877A 2000-06-16 2001-06-15 Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares AR028959A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21211700P 2000-06-16 2000-06-16

Publications (1)

Publication Number Publication Date
AR028959A1 true AR028959A1 (es) 2003-05-28

Family

ID=22789625

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102877A AR028959A1 (es) 2000-06-16 2001-06-15 Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares

Country Status (19)

Country Link
US (1) US20020013335A1 (es)
EP (1) EP1292302A2 (es)
JP (1) JP2003535899A (es)
KR (1) KR20030010710A (es)
CN (1) CN1436076A (es)
AR (1) AR028959A1 (es)
AU (2) AU2001268446B2 (es)
BR (1) BR0111601A (es)
CA (1) CA2412636A1 (es)
CZ (1) CZ20024115A3 (es)
EA (1) EA200300027A1 (es)
HU (1) HUP0301244A3 (es)
IL (1) IL153405A0 (es)
MX (1) MXPA02012410A (es)
NO (1) NO20026008D0 (es)
NZ (1) NZ523114A (es)
PL (1) PL365455A1 (es)
WO (1) WO2001097809A2 (es)
ZA (1) ZA200300418B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2269604T (lt) 2001-02-19 2016-11-10 Novartis Ag Inkstų solidinių navikų gydymas rapamicino dariniu
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
PL216224B1 (pl) 2002-02-01 2014-03-31 Ariad Pharmaceuticals Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
KR101131794B1 (ko) 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
NZ538781A (en) * 2002-09-17 2007-11-30 Wyeth Corp Oral formulations
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US7728033B2 (en) 2003-05-05 2010-06-01 Clinigene International Private Limited Mycophenolate mofetil in diabetic nephropathy
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
DE102004019845A1 (de) * 2004-03-29 2005-10-20 Krka Tovarna Zdravil D D Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
CN100435755C (zh) * 2004-07-27 2008-11-26 微创医疗器械(上海)有限公司 药物洗脱支架
EP1656941A1 (en) * 2004-11-09 2006-05-17 Clinigene International Private Limited Compositions for the treatment of diabetic nephropathy
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
CN100384416C (zh) * 2006-03-20 2008-04-30 杨军 一种用于治疗心血管疾病的药物组合物
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
WO2015103447A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CN102803189B (zh) 2010-03-15 2016-01-20 埃克森美孚化学专利公司 用于生产醇的方法
CA2926747A1 (en) * 2012-10-12 2014-04-17 Arlan RICHARDSON Use of mtor inhibitors to treat vascular cognitive impairment
US10098871B2 (en) * 2013-03-15 2018-10-16 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN105997940A (zh) * 2016-05-11 2016-10-12 中国人民解放军第三军医大学 炎症微环境响应性纳米药物、其制备方法及应用
CN117224557A (zh) * 2023-11-02 2023-12-15 中国人民解放军空军军医大学 柚皮苷联合雷帕霉素在制备治疗高脂血症的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
RU2184541C2 (ru) * 1997-06-13 2002-07-10 Американ Хоум Продактс Корпорейшн Препараты рапамицина для орального применения
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin

Also Published As

Publication number Publication date
CN1436076A (zh) 2003-08-13
NZ523114A (en) 2004-07-30
JP2003535899A (ja) 2003-12-02
HUP0301244A2 (hu) 2003-08-28
AU6844601A (en) 2002-01-02
CA2412636A1 (en) 2001-12-27
NO20026008L (no) 2002-12-13
KR20030010710A (ko) 2003-02-05
CZ20024115A3 (cs) 2003-06-18
MXPA02012410A (es) 2003-04-25
WO2001097809A3 (en) 2002-05-10
EP1292302A2 (en) 2003-03-19
WO2001097809A2 (en) 2001-12-27
EA200300027A1 (ru) 2003-06-26
AU2001268446B2 (en) 2005-08-11
IL153405A0 (en) 2003-07-06
PL365455A1 (en) 2005-01-10
BR0111601A (pt) 2003-07-01
HUP0301244A3 (en) 2005-01-28
US20020013335A1 (en) 2002-01-31
NO20026008D0 (no) 2002-12-13
ZA200300418B (en) 2004-04-15

Similar Documents

Publication Publication Date Title
AR028959A1 (es) Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR023715A1 (es) Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
AR052221A1 (es) Metodo para el tratamiento de la enfermedad poliquistosis renal
AR032293A1 (es) Estuche farmaceutico
ECSP045025A (es) Combinación de opioides seleccionados con antagonistas muscarnicos para el tratamiento de la incontinencia urinaria
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
ES2195939T3 (es) Composicion para prevencion y/o tratamiento de trastornos circulatorios que comprende derivados de l-carnitina y extractos de ginkgo biloba.
PT1150704E (pt) Melagatran para o tratamento da inflamacao
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
EA200300639A1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
SE0000303D0 (sv) Novel compounds
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
FR2839450B1 (fr) Preparation medicamenteuse notamment pour le traitement des hernies discales
UY26930A1 (es) Amidas de ácido fenilciclohexanocarboxílico sustituido y su uso
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer
WO2004012732A3 (en) Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy

Legal Events

Date Code Title Description
FA Abandonment or withdrawal